Treatment of LA Grade B Esophagitis
LA Grade B esophagitis requires daily proton pump inhibitor (PPI) therapy for initial healing, followed by continuous daily maintenance therapy at the lowest effective dose—not on-demand or less-than-daily dosing. 1
Initial Treatment Approach
Start with once-daily PPI therapy (e.g., esomeprazole 40 mg, omeprazole 20 mg) taken 30-60 minutes before breakfast for 4-8 weeks 2. LA Grade B esophagitis represents conclusive evidence of GERD with 100% objective GERD confirmation on pH monitoring studies 3, and shows high response rates to acid suppression (75-82.7%) 4.
If Inadequate Response at 4-8 Weeks:
- Verify medication compliance and timing
- Increase to twice-daily PPI (before breakfast and dinner), though not FDA-approved 2
- Alternatively, switch to a more potent acid suppressive agent 2
Maintenance Therapy (Critical)
Once healed, continuous daily PPI therapy is mandatory for LA Grade B esophagitis 1. This is a Grade A recommendation based on strong evidence showing:
- High recurrence rates of erosive disease without continuous therapy
- Randomized trials demonstrate dramatic reduction in esophagitis recurrence with daily PPI treatment
- On-demand or less-than-daily dosing is specifically contraindicated (Grade D recommendation) for patients with documented erosive esophagitis 1
Titrate to the lowest effective daily dose that maintains symptom control and mucosal healing 1, 2. This may be half the healing dose, but must remain daily.
Key Clinical Pitfalls
Do not use on-demand therapy for LA Grade B esophagitis. While on-demand therapy works for non-erosive GERD, it leads to high recurrence rates in erosive disease 1. This is a common error—LA Grade B requires continuous daily dosing unlike LA Grade A (borderline GERD) where on-demand therapy may be appropriate 2.
Adjunctive Measures
- Weight management and lifestyle modifications (elevate head of bed, avoid late meals, reduce trigger foods)
- Consider alginate antacids for breakthrough symptoms
- Nighttime H2-receptor antagonists if nocturnal symptoms persist 2
Long-term Monitoring
- No routine endoscopic surveillance is recommended for disease progression monitoring 1
- Risk of Barrett's esophagus development is low (~1.9% over 7 years with healed mucosa) 1
- If on chronic PPI therapy beyond 12 months, consider reflux testing to confirm appropriateness of long-term therapy 2
Why This Matters for Outcomes
LA Grade B esophagitis without continuous therapy leads to recurrent mucosal injury, potential stricture formation, and persistent symptoms that significantly impair quality of life. The evidence strongly supports that continuous daily PPI therapy prevents these complications and maintains symptom control, directly impacting morbidity and quality of life 1, 3.